Molnupiravir: coding for catastrophe.

@article{Malone2021MolnupiravirCF,
  title={Molnupiravir: coding for catastrophe.},
  author={Brandon Malone and Elizabeth A. Campbell},
  journal={Nature structural \& molecular biology},
  year={2021},
  volume={28 9},
  pages={
          706-708
        }
}
Approaches to the Potential Therapy of COVID-19: A General Overview from the Medicinal Chemistry Perspective
In spite of advances in vaccination, control of the COVID-19 pandemic will require the use of pharmacological treatments against SARS-CoV2. Their development needs to consider the existence of two
Covariant Fitness Clusters Reveal Structural Evolution of SARS-CoV-2 Polymerase Across the Human Population
TLDR
GPR principled SCV provides a generalizable tool to mechanistically understand evolution of viral genomes at atomic resolution contributing to fitness at the pathogen-host interface.
Review on molnupiravir as a promising oral drug for the treatment of COVID-19
TLDR
Molecular docking analysis on molnupiravir is examined, the mechanism of action (MOA), the recent synthetic pathway is reported, and this review will be helpful to different disciplines such as medicinal chemistry, organic chemistry, biochemistry, and pharmacology.
The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2
TLDR
A review of studies over the last two years that reveal the impact of point mutations, insertions/deletions, and intratypic/intertypic homologous and non-homologous recombination events on the evolution of CoVs, and whether the next generations of CoV vaccines should be directed against other CoV proteins in addition to or instead of spike.
Very low levels of remdesivir resistance in SARS-COV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis
TLDR
Very low levels of remdesivir resistance worldwide despite massive usage of antiviral compounds during the COVID19 pandemic are revealed.
COVID -19: REPLICATION INHIBITORS AS PROMISING THERAPY FOR SYMPTOMATIC PATIENTS
COVID-19 is unprecedented pandemic threading the mankind existence in the recent time, with globally reported (256,966,237) confirmed cases, including (5,151,643) death, as of 22 of November
Editorial: Multisystem Inflammatory Syndrome in Adults (MIS-A) and the Spectrum of COVID-19
  • D. Parums
  • Medicine
    Medical science monitor : international medical journal of experimental and clinical research
  • 2021
TLDR
COVID-19 is described as a spectrum of hyperinflammatory disease in terms of severity, extent, duration, and patient age and patients with MIS-A may respond to supportive therapies that control hyper inflammation.
Enzymatic Catalysts to Combat COVID-19
TLDR
Molnupiravir is an orally available antiviral agent with clinical efficacy against COVID-19 and an isobutyl ester at the 5′-position of the ribose sugar helps the drug permeate the gut so it can liberate the active agent (N-hydroxycytidine) in the bloodstream.
Identification and Semisynthesis of (–)-Anisomelic Acid as an Oral Antiviral Agent against SARS-CoV-2 in Mice
(–)-Anisomelic acid (AA), isolated from Anisomeles indica (L.) Kuntze (Labiatae) leaves, is a macrocyclic cembranolide with a trans-fused α-methylene-β-lactone motif. Cytopathic effect assays showed
...
1
2
...

References

SHOWING 1-10 OF 16 REFERENCES
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
TLDR
The molecular mechanisms underlying molnupiravir-induced RNA mutagenesis by the viral RNA-dependent RNA polymerase (RdRp) are established, and NHC can form stable base pairs with either G or A in the RdRp active center, explaining how the polymerase escapes proofreading and synthesizes mutated RNA.
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit
TLDR
The goals of the Summit were to review the current state of the science, identify unmet research needs, share insights and lessons learned from treating other infectious diseases, identify opportunities for public-private partnerships, and assist the research community in designing and developing antiviral therapeutics.
SARS-CoV-2 Infection is Effectively Treated and Prevented by EIDD-2801
TLDR
The results show that therapeutic and prophylactic administration of EIDD-2801, an oral broad spectrum antiviral currently in phase II-III clinical trials, dramatically inhibited SARS-CoV-2 replication in vivo and thus has significant potential for the prevention and treatment of COVID-19.
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19
TLDR
Considering the high conservation of RdRp among coronaviruses, an improved knowledge of its activity in vitro can provide useful information for drug development or drug repurposing to combat SARS-CoV-2 as well as future pandemics.
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
A ribonucleoside analog inhibits SARS-CoV-2 in human airway epithelial cell cultures and SARS-CoV and MERS-CoV in mice. Catastrophic consequences Broad-spectrum antivirals are desirable, particularly
Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
TLDR
The results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analogue as a direct-acting antiviral.
Role of different tautomers in the base-pairing abilities of some of the vital antiviral drugs used against COVID-19.
  • N. R. Jena
  • Medicine, Chemistry
    Physical chemistry chemical physics : PCCP
  • 2020
TLDR
It is shown that Remdesivir, a nucleoside drug that was originally invented for the Ebola virus, is effective in suppressing the replication of SARS-CoV-2 that causes COVID-19.
Analysis of the Potential for N4-Hydroxycytidine To Inhibit Mitochondrial Replication and Function
TLDR
It is demonstrated that the 5′-triphosphate of NHC can be used by POLRMT for incorporation into nascent RNA chain but does not cause immediate chain termination, and is not the main contributor to the compound’s observed cytotoxicity in these cell lines.
Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia
TLDR
EIDD-2801 is created, an isopropylester prodrug of the ribonucleoside analog N4-hydroxycytidine that has shown broad anti-influenza virus activity in cultured cells and mice and is recommended as a clinical candidate with high potential for monotherapy of seasonal and pandemic influenza virus infections.
...
1
2
...